Q1 2026 · 13F-HR
DEERFIELD MANAGEMENT COMPANY, L.P.holdings as filed
Filed 2026-05-15 · accession 0001213900-26-057678
$8.48B
Reported value
82
Positions
2026-03-31
Period end
The Brief · DEERFIELD MANAGEMENT COMPANY, L.P. · Q1 2026
AI · grounded in 13F
Deerfield Management Company, L.P. closed its position in Indivior PLC, reducing exposure by $121.7M. The fund established a new position in Arrowhead Pharmaceuticals In [[stock:ARWR 0 01/15/32]] valued at $207.2M. Other new entries include Indivior Pharmaceuticals Inc INDV at $94.4M and Syndax Pharmaceuticals Inc at $88.3M. Additionally, the fund trimmed its holdings in Neurocrine Biosciences Inc NBIX by 48.5%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670703107 | NUVL | NUVALENT INC | $1.77B | 20.8% | 17,248,450 | Common | SOLE |
| 112463AF1 | BKD 3.5 10/15/29 | BROOKDALE SR LIVING INC | $505.4M | 5.96% | 306,885,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $348.1M | 4.11% | 9,043,903 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $310.4M | 3.66% | 963,351 | Common | SOLE |
| 92556V106 | VTRS | VIATRIS INC | $273.0M | 3.22% | 20,206,170 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $271.0M | 3.20% | 457,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $223.4M | 2.64% | 2,297,000 | Common | SOLE |
| 604749AB7 | MIRM 4 05/01/29 | MIRUM PHARMACEUTICALS INC | $209.4M | 2.47% | 70,000,000 | Common | SOLE |
| 04280AAC4 | ARWR 0 01/15/32 | ARROWHEAD PHARMACEUTICALS IN | $207.2M | 2.44% | 200,000,000 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $195.6M | 2.31% | 1,714,000 | Common | SOLE |
| 15135B101 | CNC | CENTENE CORP DEL | $193.7M | 2.29% | 5,917,091 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $160.2M | 1.89% | 35,606,974 | Common | SOLE |
| 112463104 | BKD | BROOKDALE SR LIVING INC | $159.2M | 1.88% | 11,637,032 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $149.7M | 1.77% | 3,722,100 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $148.7M | 1.75% | 1,979,669 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $143.2M | 1.69% | 15,038,000 | Common | SOLE |
| 457730109 | INSP | INSPIRE MED SYS INC | $139.4M | 1.64% | 2,703,238 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $139.1M | 1.64% | 7,687,638 | Common | SOLE |
| 00653Q102 | AHCO | ADAPTHEALTH CORP | $136.6M | 1.61% | 11,477,730 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $136.5M | 1.61% | 4,264,789 | Common | SOLE |
| 00404A109 | ACHC | ACADIA HEALTHCARE COMPANY IN | $105.7M | 1.25% | 4,520,000 | Common | SOLE |
| 04280A100 | ARWR | ARROWHEAD PHARMACEUTICALS IN | $98.6M | 1.16% | 1,573,297 | Common | SOLE |
| 14888U101 | CPRX | CATALYST PHARMACEUTICALS INC | $97.6M | 1.15% | 3,943,600 | Common | SOLE |
| 45579U109 | INDV | INDIVIOR PHARMACEUTICALS INC | $94.4M | 1.11% | 3,097,790 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $94.0M | 1.11% | 1,615,696 | Common | SOLE |
| 462222AF7 | IONS 1.75 06/15/28 | IONIS PHARMACEUTICALS INC | $90.6M | 1.07% | 60,000,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $88.3M | 1.04% | 3,126,042 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $88.3M | 1.04% | 3,779,900 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $86.8M | 1.02% | 4,146,813 | Common | SOLE |
| 01625VAB0 | ALHC 4.25 11/15/29 | ALIGNMENT HEALTHCARE INC | $85.9M | 1.01% | 61,000,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $85.6M | 1.01% | 1,019,813 | Common | SOLE |
| 717081103 | PFE | PFIZER INC | $85.4M | 1.01% | 3,040,000 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $80.4M | 0.95% | 610,000 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $79.8M | 0.94% | 3,723,131 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $74.1M | 0.87% | 13,569,000 | Common | SOLE |
| 98937LAA3 | ZBIO 2.5 04/01/32 | ZENAS BIOPHARMA INC | $67.3M | 0.79% | 65,000,000 | Common | SOLE |
| 29332G102 | EHABUSD | ENHABIT INC | $66.9M | 0.79% | 4,747,746 | Common | SOLE |
| 64049MAB6 | NEO 0.25 01/15/28 | NEOGENOMICS INC | $66.7M | 0.79% | 72,689,000 | Common | SOLE |
| 372303206 | GMAB | GENMAB A/S | $66.1M | 0.78% | 2,462,000 | Common | SOLE |
| 090572207 | BIO | BIO RAD LABS INC | $63.0M | 0.74% | 226,070 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HLDGS INC | $62.8M | 0.74% | 827,999 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $60.3M | 0.71% | 7,503,812 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $59.4M | 0.70% | 1,823,500 | Common | SOLE |
| 29415F104 | NVST | ENVISTA HOLDINGS CORPORATION | $56.1M | 0.66% | 2,210,100 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $51.0M | 0.60% | 1,530,008 | Common | SOLE |
| 07782B104 | BLTE | BELITE BIO INC | $48.5M | 0.57% | 304,013 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $48.1M | 0.57% | 851,556 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $46.7M | 0.55% | 561,170 | Common | SOLE |
| 15687V109 | CERT | CERTARA INC | $44.5M | 0.53% | 7,808,605 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $43.7M | 0.52% | 4,885,446 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $42.0M | 0.50% | 657,000 | Common | SOLE |
| 53802LAB8 | LIVN 2.5 03/15/29 | LIVANOVA PLC | $40.0M | 0.47% | 34,280,000 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $38.9M | 0.46% | 970,590 | Common | SOLE |
| 14167L103 | CDNA | CAREDX INC | $38.0M | 0.45% | 2,191,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $37.0M | 0.44% | 767,993 | Common | SOLE |
| 45258DAB1 | IMCR 2.5 02/01/30 | IMMUNOCORE HLDGS PLC | $27.0M | 0.32% | 30,000,000 | Common | SOLE |
| 92337F107 | VCYT | VERACYTE INC | $23.4M | 0.28% | 726,000 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $22.5M | 0.27% | 67,935 | Common | SOLE |
| 29082K105 | EMBC | EMBECTA CORP | $22.4M | 0.26% | 2,534,961 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $21.0M | 0.25% | 549,000 | Common | SOLE |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $21.0M | 0.25% | 4,394,367 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $20.7M | 0.24% | 283,000 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $19.1M | 0.23% | 3,606,000 | Common | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $17.7M | 0.21% | 323,745 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $17.3M | 0.20% | 2,000,000 | Common | SOLE |
| 85220G109 | SGP | SPYGLASS PHARMA INC | $14.3M | 0.17% | 550,000 | Common | SOLE |
| 08659B102 | BBNX | BETA BIONICS INC | $13.3M | 0.16% | 1,324,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $12.2M | 0.14% | 2,722,165 | Common | SOLE |
| 68236X100 | TOI | THE ONCOLOGY INSTITUTE INC | $10.3M | 0.12% | 3,360,052 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $5.5M | 0.06% | 386,169 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $3.2M | 0.04% | 583,913 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $2.3M | 0.03% | 1,055,192 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $1.9M | 0.02% | 92,787 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $1.1M | 0.01% | 13,702 | Common | SOLE |
| 09090D509 | PHGE | BIOMX INC | $492,795 | 0.01% | 131,272 | Common | SOLE |
| 922967104 | MANE | VERADERMICS INC | $315,750 | 0.00% | 5,000 | Common | SOLE |
| 444859102 | HUM | HUMANA INC | $158,999 | 0.00% | 917 | Common | SOLE |
| 68236X118 | TOIIW | THE ONCOLOGY INSTITUTE INC | $54,750 | 0.00% | 1,250,000 | Common | SOLE |
| 74765K113 | QSIAW | QUANTUM SI INC | $36,200 | 0.00% | 333,333 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $10,900 | 0.00% | 8,790 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $2,667 | 0.00% | 166,666 | Common | SOLE |
| 62855J104 | MYGN | MYRIAD GENETICS INC | $2,273 | 0.00% | 505 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.